RET fusion positive cancer
MONDO:0700216Neoplasm associated with expression of a RET (REarranged during Transfection) fusion. RET fusion-positive tumors have been identified in a broad range of solid tumor types, including multiple endocrine neoplasia 2 (MEN2), papillary thyroid carcinoma (PTC), non-small cell lung cancer (NSCLC), invasive breast cancers, and pancreatic ductal adenocarcinomas in addition to colorectal adenocarcinoma, melanoma, small cell lung cancer, neuroblastoma, and small intestine neuroendocrine tumors.
Also known as: RET fusion positive neoplasm, RET fusion positive solid tumor, RET fusion positive solid tumour
1450 clinical trials for this condition and its sub-types, 20 tagged with RET fusion positive cancer itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Can a targeted pill be safely used for RET-Driven cancers in india?
Disease control Not yet recruitingResearchers are studying the safety of selpercatinib, an oral drug, in people in India with advanced cancers that have changes in the RET gene. The trial includes adults with RET fusion-positive non-small cell lung cancer and adults and children aged 12 and older with RET-mutant …
Phase 4 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control Not yet recruitingThis early-phase study tests an oral drug called SNH-118110 in 240 adults with advanced solid tumors that have a specific genetic change (RET). The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants must have tried other treatm…
Phase 1 • Sponsor: ScinnoHub Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a simple pill prevent a common side effect of targeted lung cancer therapy?
Disease control Not yet recruitingThis study looks at whether taking leucogen (a drug that raises white blood cell counts) from the start can prevent low white blood cells in people with RET fusion-positive non-small cell lung cancer who are taking pralsetinib. About 25 people who have not had prior treatment wil…
Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC